Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 21, 2026
TickeronGET DAILY SIGNALS
Healthcare Services Group (HCSG) Reports Solid Q3 Earnings and Raises 2027 Outlook

Healthcare Services Group (HCSG) Reports Solid Q3 Earnings and Raises 2027 Outlook

Key Takeaways

  • Healthcare Services Group reported third-quarter 2026 revenue of $479.6 million, up about 3.3% from $464.3 million a year earlier.
  • Diluted earnings per share (EPS) came in at $0.36, down from $0.59 in the prior-year quarter but well ahead of analyst expectations.
  • The company completed its $93.5 million acquisition of NEXDINE Hospitality in October, adding an expected $150 million-plus in annual revenue.
  • Management guided fourth-quarter revenue to $535 million to $545 million and raised its 2027 growth outlook to low double digits.
  • Cost of services remained well below the company's 86% target at 83.2% of revenue, supported by strong execution and lower bad-debt expense.
  • The company repurchased $11.7 million of stock in the quarter, bringing its year-to-date buyback total to $56.6 million.

Earnings Context and Why It Matters

Healthcare Services Group (HCSG) provides housekeeping, laundry, and dining services to healthcare, senior living, and campus facilities. Its quarterly results give insight into demand trends in the senior-care sector, where long-term demographic shifts are starting to take shape. This third-quarter update also arrives shortly after the close of the NEXDINE Hospitality acquisition, which expands the company's presence in senior living and hospitality markets. For investors, the report sheds light on organic growth, cost control, and capital allocation across acquisitions and share repurchases.

Reported Results

For the three months ended September 30, 2026, HCSG posted revenue of $479.6 million versus $464.3 million in the year-ago period. Environmental Services revenue reached $217.2 million with a 13.3% segment margin, while Dietary Services revenue was $262.4 million with an 8.7% segment margin. Cost of services came in at $399.2 million, or 83.2% of revenue, and SG&A expenses totaled $49.1 million, or 10.2% of revenue after adjusting for a $600,000 decline in deferred compensation. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Net income was $24.9 million, compared with $42.9 million a year earlier, and diluted EPS was $0.36 versus $0.59. The prior-year quarter included higher other income. The effective tax rate stood at 26.2%, with management expecting roughly 25% for the full year 2026. Even with the year-over-year drop, EPS comfortably beat consensus estimates near $0.22, helped by a $6.1 million recovery tied to the Genesis bankruptcy and bad-debt expense falling below 0.5% of revenue.

Market Reaction and Investor Sentiment

Before the release, attention focused on whether HCSG could maintain sequential revenue growth while keeping costs in check. The company delivered its ninth sequential revenue increase in the past ten quarters, and EPS significantly exceeded expectations, which should support sentiment. Shares had risen about 12.5% year-to-date heading into the announcement, roughly matching the broader market.

Post-release attention turned to the forward view. Management lifted 2027 revenue growth guidance from mid-single digits to low double digits and highlighted immediate accretion from NEXDINE Hospitality. Investors are also weighing risks such as variability in bad-debt expense, energy and supply cost swings, and the pace of acquisition integration.

Forward Outlook and Key Factors to Monitor

Management guided fourth-quarter 2026 revenue to $535 million–$545 million, incorporating both organic growth and the NEXDINE contribution, which is expected to add more than $150 million in annual revenue at margins similar to the core business. This implies a larger sequential revenue increase than the $8 million–$9 million steps seen in recent quarters.

Looking ahead, the 2027 revenue growth target was raised to low double digits from a prior mid-single-digit outlook. This rests on mid-single-digit organic growth, client retention above 90%, a solid new-business pipeline, and the aging U.S. population entering senior-care settings.

Several items warrant watching in coming quarters. Cost of services, targeted near 86% of revenue, will test operational discipline, as will SG&A, where the long-term aim is 8.5%–9.5% of revenue. The speed of NEXDINE integration and its margin impact, any further Genesis bankruptcy developments, the loss of interest income on acquisition funding, and payroll accrual timing (which affects fourth-quarter cash flow before reversing in early 2027) are all worth monitoring.

Using Tickeron’s AI Tools in My Research

When analyzing earnings like these, I find Tickeron’s AI Screener helpful for quickly comparing HCSG against peers on fundamentals, technical patterns, and recent performance. It lets me scan for similar opportunities in the sector without spending hours on manual filtering, which keeps my process efficient and data-driven.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HCSG

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


HCSG's RSI Oscillator ascends from oversold territory

The RSI Oscillator for HCSG moved out of oversold territory on October 01, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 38 similar instances when the indicator left oversold territory. In 28 of the 38 cases the stock moved higher. This puts the odds of a move higher at 74%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on HCSG as a result. In 55 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.

The Moving Average Convergence Divergence (MACD) for HCSG just turned positive on October 06, 2026. Looking at past instances where HCSG's MACD turned positive, the stock continued to rise in 29 of 45 cases over the following month. The odds of a continued upward trend are 64%.

HCSG moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +2.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where HCSG advanced for three days, in 196 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HCSG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.

HCSG broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for HCSG entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.872) is normal, around the industry mean (204.137). P/E Ratio (12.549) is within average values for comparable stocks, (19.387). Projected Growth (PEG Ratio) (1.359) is also within normal values, averaging (2.498). Dividend Yield (0.040) settles around the average of (0.095) among similar stocks. P/S Ratio (0.840) is also within normal values, averaging (2.688).

The Tickeron SMR rating for this company is 39 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. HCSG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HCSG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 5.07B. The market cap for tickers in the group ranges from 20.9K to 99.46B. HCA holds the highest valuation in this group at 99.46B. The lowest valued company is NMMCF at 20.9K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was 0%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was 20%. BMGL experienced the highest price growth at 15%, while NIVF experienced the biggest fall at -36%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was -62%. For the same stocks of the Industry, the average monthly volume growth was 11% and the average quarterly volume growth was -33%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 46
Price Growth Rating: 52
SMR Rating: 66
Profit Risk Rating: 86
Seasonality Score: -5 (-100 ... +100)
View a ticker or compare two or three
HCSG
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of housekeeping, laundry, linen, and facility maintenance services for the long-term health care industry

Industry HospitalNursingManagement

Industry
Servicestothe Health Industry
Address
3220 Tillman Drive
Phone
+1 215 639-4274
Employees
36000
Web
https://www.hcsgcorp.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
TSMX, a 2x daily leveraged single-stock ETF (exchange-traded fund), rose roughly +19% over the trailing 30 days, rebounding sharply from mid-September lows. The fund seeks 200% of the daily return of TSM (Taiwan Semiconductor Manufacturing), meaning its moves are roughly double the underlying stock's daily swings.
Contracted revenue anchor: A roughly $3.2 billion, seven-year LNG (liquefied natural gas) supply agreement with Puerto Rico has received final approval, providing multi-year cash-flow visibility if execution stays on track. Project pipeline inflection: Upcoming milestones include the Barcarena and PortoCem power plants in Brazil, a potential Gás Sul terminal restart, and optimization of the company's modular "Fast LNG" (FLNG) liquefaction fleet.
AMD (Advanced Micro Devices) designs central processing units (CPUs), graphics processing units (GPUs), and AI accelerators, while LRCX (Lam Research) supplies the wafer-fabrication equipment used to build advanced chips. AMD has delivered strong double-digit revenue growth on AI data-center demand, but its shares trade with elevated expectations that can trigger sharp reactions around earnings.
Origination momentum: Velocity Financial enters 2026 off record annual originations of roughly $2.7 billion (up about 48%), positioning it to keep gaining share in a fragmented investor-loan market. Credit normalization is the central watch item: Nonperforming loans fell toward the 8.5% range of portfolio unpaid principal balance (UPB), but asset quality remains the primary swing factor for earnings.
Turnaround milestone ahead: Management has pointed to reaching cash generation in 2027, making the pace of cost discipline and margin recovery the central question for the stock forecast. Fresh capital supports execution: A recently announced $45.5 million equity financing, with participation from management and a single institutional investor, strengthens the balance sheet as the company funds its transformation.
NFE closed at $5.51, down -6.13% during Tuesday's regular session, extending a slide that has pushed shares near a 52-week low. Primary catalyst: the company disclosed its Fast LNG unit is offline after a gas-turbine mechanical failure, with return to service not expected until Q4.
The central $11 target is the arithmetic mean of four verified analyst price targets, rounded from roughly $10.75. With the stock near $2.06, reaching $11 would require an upside of more than 400%, an extremely large move.
The $23 central target is the rounded arithmetic mean of four verified analyst price targets, which average $23.25. The latest verified price is around $9.57, meaning the target implies roughly 140% upside—a very large move.
NXH closed down -11.17% (-$0.23) to $1.83 on Oct 6, the most recent regular session, extending a steep two-day decline. Selling continued as investors digested the mutual termination of the Fathom Holdings merger and a dilutive $45.5M registered direct offering of ~16.5M shares at $2.76.
AMD is a large-cap designer of CPUs (central processing units) and GPUs (graphics processing units) competing directly with Nvidia in the AI accelerator market, while FORM is a small-cap provider of semiconductor test and measurement equipment, primarily probe cards. AMD's narrative has been driven by multi-billion-dollar hyperscaler deals, while FORM's has been powered by record revenue and sharp margin expansion tied to high-bandwidth memory (HBM) demand.
AMD has surged roughly 200% year to date, crossing a $1 trillion market capitalization on AI data-center demand and a "CPU renaissance" narrative. KLAC has gained about 71% year to date, supported by record process-control revenue and rapid growth in advanced packaging for AI chips.
AMD is a large-cap semiconductor designer riding explosive AI compute demand, while ENTG is a mid-cap supplier of materials and purity solutions that feed the same AI-driven chip cycle. AMD recently crossed a $1 trillion market capitalization on surging data center revenue, whereas ENTG operates at a far smaller scale (roughly $23 billion) with steadier, double-digit growth.
VELO closed Tuesday at $9.57, unchanged (+0.00%) from the prior session, with the move occurring during regular market hours. The flat close marked stabilization after Monday's -14.5% plunge, when shares fell to $9.57 from $11.20 following disclosure of CFO James Suva's departure.
The $8 target used here is a technical, publicly discussed recovery objective — not an analyst consensus — because legacy analyst price targets were set before NFE's restructuring and reverse stock split. New Fortress Energy Inc. ( NFE ) trades near $5.51, so reaching $8 implies a roughly 45% advance.
AVBP plunged -46.98% during Tuesday's regular session, closing at $15.09 versus $28.46, marking its worst single-day decline on record. The catalyst was the Phase 3 FURVENT trial of firmonertinib failing its primary endpoint—progression-free survival—in first-line EGFR exon 20 insertion non-small cell lung cancer.
Upcoming catalyst: The company's next earnings release is estimated for November 6, 2026, which should offer fresh detail on its SKY token holdings, staking rewards, and treasury strategy. Strategic positioning: SDEV is an on-chain holding company providing public-market exposure to the Sky protocol ecosystem, with SKY as its core digital asset and a stated focus on the stablecoin economy.
Different roles in the chip ecosystem: AMAT is a materials-engineering and deposition leader, while KLAC dominates process control, inspection, and yield management. Momentum favors AMAT: AMAT shares have more than doubled this year, while KLAC has recently pulled back roughly 9% in a month on margin and execution concerns.
Healthcare Services Group (HCSG) Reports Solid Q3 Earnings and Raises 2027 Outlook